General Information of DTT (ID: TTRZQE3)

DTT Name Glycogen synthase kinase-3 alpha (GSK-3A) DTT Info
Gene Name GSK3A

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
1 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [1]
------------------------------------------------------------------------------------
2 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [2]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [3]
------------------------------------------------------------------------------------
29 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [3]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [3]
Indazole derivative 6 DMGO1CB N. A. N. A. Patented [3]
Indirubin derivative 2 DMLX183 N. A. N. A. Patented [3]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [3]
Maleimides derivative 1 DMINM8F N. A. N. A. Patented [3]
Maleimides derivative 2 DMUVYWE N. A. N. A. Patented [3]
Maleimides derivative 3 DMEFQND N. A. N. A. Patented [3]
N-naphtyl-N-benzylurea derivative 1 DMCVBPF N. A. N. A. Patented [3]
PMID27828716-Compound-15 DM3G21F N. A. N. A. Patented [3]
PMID27828716-Compound-16 DM9VXY7 N. A. N. A. Patented [3]
PMID27828716-Compound-17 DMR7V9E N. A. N. A. Patented [3]
PMID27828716-Compound-18 DMNR6KL N. A. N. A. Patented [3]
PMID27828716-Compound-19 DM8V7QH N. A. N. A. Patented [3]
PMID27828716-Compound-20 DMDA3PN N. A. N. A. Patented [3]
PMID27828716-Compound-21 DMO1NAR N. A. N. A. Patented [3]
PMID27828716-Compound-BIO-acetoxime DMUM5L6 Malignant glioma 2A00.0 Patented [3]
Pyrazole and benzimidazole derivative 1 DM05S2X N. A. N. A. Patented [3]
Pyrazolodihydropyridine derivative 1 DMKYX7J N. A. N. A. Patented [3]
Quinoline derivative 14 DMSRB8M N. A. N. A. Patented [3]
Quinoline derivative 15 DM7HD0T N. A. N. A. Patented [3]
Quinolinyl pyrazinyl urea derivative 1 DMCIKR3 N. A. N. A. Patented [3]
Quinolinyl pyrazinyl urea derivative 2 DMKJN9G N. A. N. A. Patented [3]
Spiroquinolone derivative 1 DMYJL2Z N. A. N. A. Patented [3]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [3]
Thiadiazolidindione derivative 1 DM1L3ZA N. A. N. A. Patented [3]
Thiadiazolidindione derivative 2 DM5AUL0 N. A. N. A. Patented [3]
Thiadiazolidindione derivative 3 DMNTZ93 N. A. N. A. Patented [3]
Tricyclic 5-quinolone derivative 1 DMYEDJI N. A. N. A. Patented [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 29 Patented Agent(s)
5 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
6-bromoindirubin-3-oxime DM12WYV Discovery agent N.A. Investigative [4]
AR-534 DMNJ632 Discovery agent N.A. Investigative [5]
Benzofuran-3-yl-(indol-3-yl)maleimides DMNVG1M Discovery agent N.A. Investigative [6]
Lithium chloride DMHYLQ2 Discovery agent N.A. Investigative [7]
SB216763 DMIYFQ5 Discovery agent N.A. Investigative [8]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76.
2 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
3 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
4 Stable generation of serum- and feeder-free embryonic stem cell-derived mice with full germline-competency by using a GSK3 specific inhibitor. Genesis. 2009 Jun;47(6):414-22.
5 A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest. 2009 May;119(5):1382-95.
6 From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 2009 Apr 9;52(7):1853-63.
7 Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol. 2007 Mar;2(1):93-6.
8 Intracellular protein phosphorylation in eosinophils and the functional relevance in cytokine production. Int Arch Allergy Immunol. 2009;149 Suppl 1:45-50.